Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity.

Mocikat, R; Selmayr, M; Thierfelder, S; Lindhofer, H

Mocikat, R; Selmayr, M; Thierfelder, S; Lindhofer, H.

Affiliation

Mocikat R; GSF-Institut für Immunologie, München, Germany. mocikat@gsf.de

Cancer Res ; 57(12): 2346-9, 1997 Jun 15.

Article in En | MEDLINE | ID: mdl-9192805

Subject(s)

Cancer Vaccines/therapeutic use; Lymphoma, B-Cell/prevention & control; Vaccination; Animals; Antibodies, Bispecific/biosynthesis; Antigen-Presenting Cells/immunology; CD4-Positive T-Lymphocytes/physiology; CD8-Positive T-Lymphocytes/physiology; Female; Hybridomas; Immunoglobulin Idiotypes/biosynthesis; Lymphoma, B-Cell/immunology; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Rats; Survival Rate; Tumor Cells, Cultured

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, B-Cell / Vaccination / Cancer Vaccines Limits: Animals Language: En Journal: Cancer Res Year: 1997 Document type: Article Affiliation country: Germany Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links